NEW YORK (TheStreet) -- Agenus
(AGEN) shares are up 16.7% to $3.75 on Tuesday after the company announced that its experimental cancer vaccine helped patients with brain tumors live twice as long as those that received treatment without the vaccine.
Fifty percent of newly diagnosed glioblastoma multiforme (GBM) patients treated with the vaccine had their median overall survival time increased to two years in a mid-stage study.
Most GBM patients succumb to the disease within one year.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts